Eli Lilly and Co (NYSE:LLY) said on Monday it is lowering the cash prices of its weight-loss drug Zepbound, marking the latest move in a growing price battle with rival Novo Nordisk.
The US pharmaceutical giant said single-dose vials of Zepbound will now be available on its direct-to-consumer platform, LillyDirect, at reduced prices.
Patients with a prescription can purchase the starting 2.5 mg dose for $299 per month, down from $349. The 5 mg dose drops to $399 from $499, while higher doses will now cost $449 per month under Lilly’s Zepbound Self Pay Journey Program, compared with the previous $499.
The price cuts follow similar reductions by Novo Nordisk for cash buyers of its top-selling weight-loss drugs Ozempic and Wegovy, intensifying competition in the growing obesity treatment market.
The announcements also come weeks after US President Donald Trump reached agreements with Eli Lilly and Novo Nordisk aimed at making GLP-1 drugs more accessible and affordable for US patients.
Eli Lilly’s shares have climbed more than 39% this year, bolstered by strong demand for obesity treatments.